Abstract
In This Issue| May 02 2022 In This Issue Author & Article Information Online ISSN: 2159-8290 Print ISSN: 2159-8274 ©2022 American Association for Cancer Research.2022American Association for Cancer Research. Cancer Discov (2022) 12 (5): 1171–1173. https://doi.org/10.1158/2159-8290.CD-12-5-ITI Related Content A commentary has been published: The Genomics of Colorectal Cancer in Populations with African and European Ancestry A commentary has been published: The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies A commentary has been published: Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors View more A commentary has been published: Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements A commentary has been published: EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma A commentary has been published: Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer A commentary has been published: Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis A commentary has been published: Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma A commentary has been published: Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record May 2 2022 Citation In This Issue. Cancer Discov 1 May 2022; 12 (5): 1171–1173. https://doi.org/10.1158/2159-8290.CD-12-5-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Neuregulin 1 (NRG1) fusion proteins, which occur in many tumor types, bind HER3 and induce its dimerization with other HER/ERBB kinases, thereby promoting downstream oncogenic signaling and tumorigenesis. Because targeting HER2 and/or HER3 has been shown to be effective in NRG1-rearranged tumor models, Schram, Odintsov, and colleagues investigated zenocutuzumab, a HER2xHER3 bispecific antibody, in NRG1-rearranged tumors. In preclinical models of lung, breast, pancreas, and ovarian NRG1-rearranged tumors, zenocutuzumab reduced cell growth and HER3 and AKT phosphorylation and induced apoptosis. Three patients with NRG1 fusion–positive metastatic cancers were treated with zenocutuzumab and had a partial response, supporting its ongoing clinical evaluation in NRG1 fusion–positive cancers. See article, p. 1233. PD-1/PD-L1 blockade reportedly synergizes with agonists targeting the costimulatory molecule 4-1BB on primed CD8+ T cells. Muik and colleagues report the preclinical characterization and phase I results of GEN1046, a bispecific antibody designed to elicit an antitumor... You do not currently have access to this content.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
